NeoGenomics Investor Day - Speakers
Chris Smith, CEO
Chris joins NeoGenomics from OrthoClinical Diagnostics where he served as Chairman and CEO from 2019 to May of 2022. During his leadership, OrthoClinical raised $1.45 billion in funding in a Q1 2021 initial public offering and achieved accelerated revenue growth from 1% annually to low double-digit levels while simultaneously improving profitability. Chris also successfully guided the company through a combination with Quidel that closed in May 2022.
Prior to OrthoClinical, Chris served in key executive leadership positions at Cochlear Limited, a global market leader in implantable hearing solutions with over $1.2 billion in annual revenue. Having initially joined Cochlear as President of Cochlear Americas in 2004, Chris helped grow division revenue from $80 million to over $400 million before being named CEO in 2015. During his tenure as CEO from 2015 to 2018, Chris oversaw a 35% organic improvement in annual revenues and improved profitability.
Chris joins NeoGenomics from OrthoClinical Diagnostics where he served as Chairman and CEO from 2019 to May of 2022. During his leadership, OrthoClinical raised $1.45 billion in funding in a Q1 2021 initial public offering and achieved accelerated revenue growth from 1% annually to low double-digit levels while simultaneously improving profitability. Chris also successfully guided the company through a combination with Quidel that closed in May 2022.
Prior to OrthoClinical, Chris served in key executive leadership positions at Cochlear Limited, a global market leader in implantable hearing solutions with over $1.2 billion in annual revenue. Having initially joined Cochlear as President of Cochlear Americas in 2004, Chris helped grow division revenue from $80 million to over $400 million before being named CEO in 2015. During his tenure as CEO from 2015 to 2018, Chris oversaw a 35% organic improvement in annual revenues and improved profitability.
Jeff Sherman, CFO
Jeff has over 32 years of finance experience in the healthcare services industry, having gained a well-rounded background from serving in finance roles at public companies of different sizes and at different growth stages in their lifecycle. While he has most recently served as Chief Financial Officer of Privia Health Group, Inc., a national physician enablement company, Jeff has also served as the Chief Financial Officer at three other organizations: HMS, a technology analytics and engagement solutions provider for government and commercial healthcare payers; AccentCare, a multi-state community-based healthcare delivery organization; and LIFEPOINT Health, a non-urban private hospital company operating 72 hospitals. Jeff also held various finance roles of increasing scope and responsibility at Tenet Healthcare Corporation.
Jeff received a B.A. in Finance/Accounting from the University of Colorado, Boulder, and an MBA from the University of Southern California.
Jeff has over 32 years of finance experience in the healthcare services industry, having gained a well-rounded background from serving in finance roles at public companies of different sizes and at different growth stages in their lifecycle. While he has most recently served as Chief Financial Officer of Privia Health Group, Inc., a national physician enablement company, Jeff has also served as the Chief Financial Officer at three other organizations: HMS, a technology analytics and engagement solutions provider for government and commercial healthcare payers; AccentCare, a multi-state community-based healthcare delivery organization; and LIFEPOINT Health, a non-urban private hospital company operating 72 hospitals. Jeff also held various finance roles of increasing scope and responsibility at Tenet Healthcare Corporation.
Jeff received a B.A. in Finance/Accounting from the University of Colorado, Boulder, and an MBA from the University of Southern California.
Vishal Sikri, President of Advanced Diagnostics
Vishal Sikri has over 20 years of experience in the somatic diagnostics space and most recently was President of Oncology at Invitae. Prior to Invitae, Vishal served as U.S. General Manager for Biocartis leading all commercial operations. He has extensive precision medicine experience, having launched and commercialized tests for therapy selection and molecular residual disease in the U.S. and globally across different molecular platforms. Vishal brings years of proven success as a dynamic leader in large organizations. He holds degrees in Molecular Biology and Pharmaceutical Sciences from UW-Madison and an MBA from Loyola University.
Vishal Sikri has over 20 years of experience in the somatic diagnostics space and most recently was President of Oncology at Invitae. Prior to Invitae, Vishal served as U.S. General Manager for Biocartis leading all commercial operations. He has extensive precision medicine experience, having launched and commercialized tests for therapy selection and molecular residual disease in the U.S. and globally across different molecular platforms. Vishal brings years of proven success as a dynamic leader in large organizations. He holds degrees in Molecular Biology and Pharmaceutical Sciences from UW-Madison and an MBA from Loyola University.
Warren Stone, President of Clinical Division
Warren is a highly accomplished enterprise leader with extensive global experience in the Life Science and Diagnostic sectors, who most recently served as President of Americas at Ortho Clinical Diagnostics.
As a hands-on leader, Warren championed the development of an organizational growth culture and digital transformation of systems and tools, including a hybrid/digital go-to-market deployment model, delivering productivity, margin expansion and accelerated revenue growth. With an emphasis on customer experience, Warren's team won an independent industry ServiceTrak™ award for the 'Best Pre/Post-Sales and Customer Success in 2021 and 2022'.
Before joining Ortho, he served as Senior Vice President of Research Americas for MilliporeSigma, where he developed a commercial growth strategy, advancing the business 40% above the market. He also drove a cross-functional digital transformation to address customer needs, resulting in more than $200M in incremental revenue in 2.5 years.
Warren is a highly accomplished enterprise leader with extensive global experience in the Life Science and Diagnostic sectors, who most recently served as President of Americas at Ortho Clinical Diagnostics.
As a hands-on leader, Warren championed the development of an organizational growth culture and digital transformation of systems and tools, including a hybrid/digital go-to-market deployment model, delivering productivity, margin expansion and accelerated revenue growth. With an emphasis on customer experience, Warren's team won an independent industry ServiceTrak™ award for the 'Best Pre/Post-Sales and Customer Success in 2021 and 2022'.
Before joining Ortho, he served as Senior Vice President of Research Americas for MilliporeSigma, where he developed a commercial growth strategy, advancing the business 40% above the market. He also drove a cross-functional digital transformation to address customer needs, resulting in more than $200M in incremental revenue in 2.5 years.
Melody Harris, President of Enterprise Operations
Melody Harris joined NeoGenomics in December of 2022. She is serving as President of Enterprise Operations. Prior to that Melody was with SomaLogic and served as President and Chief Operating Officer. She oversaw life sciences markets, healthcare markets, marketing and product, operations, technology, legal and HR. Ms. Harris assisted the CEO in day-to-day management of the company both internally and external, with full P&L responsibility.
Prior to SomaLogic, Ms. Harris held executive positions in the healthcare space for Qualcomm Life (the healthcare division of Qualcomm) and HealthyCircles, a technology spin-out from Microsoft which she and team successfully sold to Qualcomm in 2013. At Qualcomm, Ms. Harris led corporate deals and M&A transactions and worked extensively across Qualcomm in leading the integration efforts of those acquisitions. Ms. Harris has led deals across the healthcare spectrum including with Merck, Telus Health Solutions, United Health Group, Novartis, Surescripts, CVS and the American Heart Association to name a few.
Prior to HealthyCircles, Ms. Harris held a variety of other executive, operational and legal leadership roles, including president of an international consumer-focused brand management firm, and executive vice president of an international software development and consulting firm in the broadcasting space.
Ms. Harris has served in multiple community and public roles including as a trustee of Metropolitan State University of Denver (gubernatorial appointment), director of the Stapleton Development Corporation (mayoral appointment), member of two Colorado gubernatorial transition committees, policy advisor to Denver Mayor Michael Hancock and member of his transition team, and energy policy advisor and lead writer of the Bill Ritter for Governor campaign’s New Energy Economy white paper in 2006.
Ms. Harris holds a Bachelor of Arts, cum laude, in Political Science from the University of Denver and a Juris Doctor, cum laude, from the Harvard Law School.
Melody Harris joined NeoGenomics in December of 2022. She is serving as President of Enterprise Operations. Prior to that Melody was with SomaLogic and served as President and Chief Operating Officer. She oversaw life sciences markets, healthcare markets, marketing and product, operations, technology, legal and HR. Ms. Harris assisted the CEO in day-to-day management of the company both internally and external, with full P&L responsibility.
Prior to SomaLogic, Ms. Harris held executive positions in the healthcare space for Qualcomm Life (the healthcare division of Qualcomm) and HealthyCircles, a technology spin-out from Microsoft which she and team successfully sold to Qualcomm in 2013. At Qualcomm, Ms. Harris led corporate deals and M&A transactions and worked extensively across Qualcomm in leading the integration efforts of those acquisitions. Ms. Harris has led deals across the healthcare spectrum including with Merck, Telus Health Solutions, United Health Group, Novartis, Surescripts, CVS and the American Heart Association to name a few.
Prior to HealthyCircles, Ms. Harris held a variety of other executive, operational and legal leadership roles, including president of an international consumer-focused brand management firm, and executive vice president of an international software development and consulting firm in the broadcasting space.
Ms. Harris has served in multiple community and public roles including as a trustee of Metropolitan State University of Denver (gubernatorial appointment), director of the Stapleton Development Corporation (mayoral appointment), member of two Colorado gubernatorial transition committees, policy advisor to Denver Mayor Michael Hancock and member of his transition team, and energy policy advisor and lead writer of the Bill Ritter for Governor campaign’s New Energy Economy white paper in 2006.
Ms. Harris holds a Bachelor of Arts, cum laude, in Political Science from the University of Denver and a Juris Doctor, cum laude, from the Harvard Law School.
.png)
Peter D. Beitsch, MD, FACS
Surgical Oncologist
Chief Executive Officer, Dallas Surgical Group
Co-founder of Targeted Medical Education
Dr. Beitsch went to medical school at University of Texas Southwestern Medical School in Dallas and finished his general surgery residency at Parkland Hospital in Dallas in 1993. He had a National Cancer Institute fellowship at M.D. Anderson Cancer Center from 1988-90. He completed his training with a surgical oncology fellowship at the John Wayne Cancer Institute in Santa Monica, California. In 1994, he returned to private practice in Dallas where his practice is focused on melanoma and breast cancer.
He has held numerous positions in national surgical societies including the American Society of Breast Surgeons where he served as the first Chairman of the Membership Committee 2001-4, Program Director for the 2005 Annual Meeting in Los Angeles, Board of Directors Member from 2006-9 and 2012-15 and was President of the Society from 2013-14. He has served on the Executive Committee of the Society of Surgical Oncology 2008-2010, General Surgical Oncology Committee of the American Board of Surgery and was a National Ultrasound Faculty for the American College of Surgeons.
Dr. Beitsch has given numerous national and international presentations and is actively involved in breast cancer and melanoma research. He has major articles in peer-reviewed medical journals including the New England Journal of Medicine, the Journal of the American Medical Association, the Proceedings of the National Academy of Science, Journal of Clinical Oncology, and the Annals of Surgical Oncology.
He is a co-founder of Targeted Medical Education and has led their research efforts. TME Research has had 14 IRB approved studies and placed over 5000 patients in trial. The Universal Breast Cancer Genetic Testing Registry led to a paper in the Journal of Clinical Oncology and helped to facilitate a change in national genetic testing guidelines.
Surgical Oncologist
Chief Executive Officer, Dallas Surgical Group
Co-founder of Targeted Medical Education
Dr. Beitsch went to medical school at University of Texas Southwestern Medical School in Dallas and finished his general surgery residency at Parkland Hospital in Dallas in 1993. He had a National Cancer Institute fellowship at M.D. Anderson Cancer Center from 1988-90. He completed his training with a surgical oncology fellowship at the John Wayne Cancer Institute in Santa Monica, California. In 1994, he returned to private practice in Dallas where his practice is focused on melanoma and breast cancer.
He has held numerous positions in national surgical societies including the American Society of Breast Surgeons where he served as the first Chairman of the Membership Committee 2001-4, Program Director for the 2005 Annual Meeting in Los Angeles, Board of Directors Member from 2006-9 and 2012-15 and was President of the Society from 2013-14. He has served on the Executive Committee of the Society of Surgical Oncology 2008-2010, General Surgical Oncology Committee of the American Board of Surgery and was a National Ultrasound Faculty for the American College of Surgeons.
Dr. Beitsch has given numerous national and international presentations and is actively involved in breast cancer and melanoma research. He has major articles in peer-reviewed medical journals including the New England Journal of Medicine, the Journal of the American Medical Association, the Proceedings of the National Academy of Science, Journal of Clinical Oncology, and the Annals of Surgical Oncology.
He is a co-founder of Targeted Medical Education and has led their research efforts. TME Research has had 14 IRB approved studies and placed over 5000 patients in trial. The Universal Breast Cancer Genetic Testing Registry led to a paper in the Journal of Clinical Oncology and helped to facilitate a change in national genetic testing guidelines.
Virtual Event
Powered by
Powered by
